Global Tinea Corporis Drugs Market Size study & Forecast, by Drugs (Anti-Fungal, Others), by Route of Administration (Oral, Topical, Parenteral), by End-Users (Hospitals, Homecare, Specialty Clinics), by Distribution Channel (Hospital Pharmacy, Online Pha

Global Tinea Corporis Drugs Market Size study & Forecast, by Drugs (Anti-Fungal, Others), by Route of Administration (Oral, Topical, Parenteral), by End-Users (Hospitals, Homecare, Specialty Clinics), by Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) and Regional Analysis, 2022-2029

Global Tinea Corporis Drugs Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Tinea corporis is a fungal infection that affects the upper layer of the skin. It can occur or be produced in any part of the body, but it is most commonly found on the legs and arms, particularly in the glabrous skin. Tinea corporis, also known as ringworm, appears on the skin as a ring structure. Trichophyton rubrum, Microsporum canis, and Epidermophyton floccosum are the fungi that cause tinea corporis. The increasing incidence of fungal infections and rising demand for antifungal drugs are key factors driving the market growth.

As per Centers for Disease Control & Prevention (CDC) estimates – as of 2019, fungal diseases resulted in more than 75,000 hospitalizations and around 9 million outpatient visits occur every year for fungal diseases. Also, rising expansion of e-pharmacies and growing healthcare spending worldwide would create lucrative growth opportunities for the market over the projected period. For instance – as per Statista - In 2021, the global e-pharma market was estimated at USD 1 billion, and it is projected to grow to USD 4.8 billion by the year 2031. However, high cost of Tinea Corporis Drugs and stringent drug approval process hinder the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Tinea Corporis Drugs Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the increasing incidence of fungal diseases of skin as well as rising healthcare spending in the region. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and increasing investment towards new product development from leading market players in the region.

Major market players included in this report are:
Novartis AG (Switzerland)
Endo International Inc (Ireland)
Teva Pharmaceutical Industries Ltd (Israel)
Glenmark Pharmaceuticals Ltd (India)
Cipla Inc (India)
Dr Reddy's Laboratories Ltd (India)
Abbott (U.S.)
F. Hoffmann-La Roche Ltd (Switzerland)
Pfizer Inc (U.S.)
Zydus Group (India)

Recent Developments in the Market:
On May 16, 2022 - Shionogi & Co., Ltd. and F2G Ltd. Entered into a strategic collaboration to develop and commercialize the new antifungal agent olorofim for invasive fungal infections in European and Asian markets. This new agent Olorofim is a novel oral antifungal therapy developed by F2G to treat invasive aspergillosis (IA) and other rare mold infections.

Global Tinea Corporis Drugs Market Report Scope:

Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Drugs, Route of Administration, End-Users, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Drugs
Anti-Fungal
Others

By Route of Administration
Oral
Topical
Parenteral

By End-Users
Hospitals
Homecare
Specialty Clinics

By Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Novartis AG (Switzerland)
Endo International Inc (Ireland)
Teva Pharmaceutical Industries Ltd (Israel)
Glenmark Pharmaceuticals Ltd (India)
Cipla Inc (India)
Dr Reddy's Laboratories Ltd (India)
Abbott (U.S.)
F. Hoffmann-La Roche Ltd (Switzerland)
Pfizer Inc (U.S.)
Zydus Group (India)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.